Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Assets (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Non-Current Assets for 13 consecutive years, with $9.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 129.89% to $9.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.1 million, a 30.91% increase, with the full-year FY2025 number at $9.6 million, up 129.89% from a year prior.
  • Non-Current Assets was $9.6 million for Q4 2025 at Niagen Bioscience, up from $4.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $9.6 million in Q4 2025 to a low of $4.2 million in Q4 2024.
  • A 5-year average of $6.5 million and a median of $6.8 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: crashed 30.37% in 2024, then skyrocketed 129.89% in 2025.
  • Niagen Bioscience's Non-Current Assets stood at $8.9 million in 2021, then decreased by 16.17% to $7.5 million in 2022, then dropped by 27.5% to $5.4 million in 2023, then dropped by 23.09% to $4.2 million in 2024, then soared by 129.89% to $9.6 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Non-Current Assets are $9.6 million (Q4 2025), $4.5 million (Q3 2025), and $4.8 million (Q2 2025).